Figure 3.

Swimmer Plots for 16 evaluable patients. Safety analysis included one additional patient (101) who withdrew from study treatment after refusing to restart LHRH analog at the time of his first off ADT PSA progression. Adaptive therapy was well tolerated with low frequency of all grades adverse events (AEs) regardless of the attribution. The most common Grade 1–2 treatment-related AEs were arthralgia, hot flashes, back pain and fatigue. One incidence of grade 3 hypertension was reported, which was attributed to abiraterone. All AEs were improved to baseline or resolved with recovery of testosterone while on the treatment break. There were no grade 4 AEs (Table 3).